Renowned French doctor Didier Raoult published new results of 1,061 coronavirus patients treated using hyroxychloroquine with 91% success rate

At this point, Dr. Didier Raoult is probably the most famous doctor in the world in the fight against coronavirus. Like him or not, Dr. Raoult has made a big difference in the lives many people around the world since he first came up with the three drug regimen of Hydroxychloroquine Sulfate, Zinc and Azithromycin (Z-Pak) to treat COVID-19 patients. His work serves as the foundation for Dr. Zelenko, who said to have effectively treaed 699 coronavirus patients with 100% success rate.

In a newly released report, Dr. Raoult found: “Hydroxychloroquine Azithromycin combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.”

Also in a post on Twitter, Dr. Raoult released the data behind his treatment of coronavirus patients. Here is what he said: “The abstract and summary table of the data in our article on the treatment of 1061 patients are online!
The abstract and the summary table of our paper on the treatment of 1061 patients are online!”

L'abstract et le tableau récapitulatif des données de notre article portant sur le traitement de 1061 patients sont en ligne !
The abstract and the summary table of our paper on the treatment of 1061 patients are online !https://t.co/mTWj6aGpTkhttps://t.co/lNXZK91etI pic.twitter.com/PLdygNolxG

— Didier Raoult (@raoult_didier) April 10, 2020

Here are his findings:

From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR. Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met our inclusion criteria. Their mean age was 43.6 years old and 492 were male (46.4%). No cardiac toxicity was observed. A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage at completion of treatment was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < 10-2) but viral culture was negative at day 10 and all but one were PCR-cleared at day 15. A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more. Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far). Poor clinical outcome was significantly associated to older age (OR 1.11), initial higher severity (OR 10.05) and low